Vera Therapeutics, Inc.
VERA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.69 | 0.21 | -0.05 | 0.20 |
| FCF Yield | -5.80% | -14.04% | -13.16% | -4.17% |
| EV / EBITDA | -13.77 | -6.52 | -4.74 | -14.43 |
| Quality | ||||
| ROIC | -26.46% | -65.53% | -81.80% | -45.23% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.96 | 0.76 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -47.06% | -36.34% | -185.38% | 32.08% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | -0.08 | 0.92 | 2.18 |
| Interest Coverage | -21.92 | 0.00 | -91.64 | -1,720.10 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 5,173.42 | -2,872.30 |